Health Populi June 30, 2021
The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue).
In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s discussion, covering:
- The macro- and micro-economics of Alzheimer’s and the $56,000 list price for the drug
- The FDA regulatory process and aftermath
- U.S. consumers’ bipartisan support for drug price regulation through Medicare negotiation and private/commercial sector adoption
- Congressional legislation addressing the price of medicines in the U.S., and
- Future prospects for value-based pricing of medicines and health care.
I concluded the essay by...
Today's Sponsors
Today's Sponsor